The global focus on gene and cell therapies has grown exponentially in recent years as more development programs have advanced to later stages or even approval. In this article published in Life Science Leader, the authors discuss the challenges for gene and cell therapy research and how new approaches to innovation and financing, such as platform diversification and partnering with academia, could help support development of cell and gene therapies. To access the article, click here.
The authors wish to acknowledge the contributions of Pascale Diesel, Stephanie Donahue, and Michael Krepps to this article.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...